HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Democrats, Republicans Agree US FDA’s Food Safety Programs Need Help, Disagree On How

Commissioner Califf Candid About Agency Funding, Abbott Nutrition Plant Problems

Executive Summary

Democrats on Oversight and Investigation Subcommittee support increasing funding for FDA’s regulation of food product manufacturing and marketing, but Republicans advise Commissioner Robert Califf the agency should do more with authority it already has and without adding to its budget.

You may also be interested in...



FDA Report On US Formula Supply Doesn’t Stop Criticism From Congress, Former Food Policy Chief

On same day agency published strategy for ensuring formula supply, House Oversight Committee subcommittee members made clear they’re not convinced FDA could prevent repeat of 2022 shortage. Recently resigned FDA food policy chief also has doubts.

US FDA Notes Concerns At Multiple Formula Plants After One Linked To Contamination, Shortage

Agency sends letters to manufacturers and other businesses involved in production and distribution “to assist industry in improving the microbiological safety of powdered infant formula.” Information from “routine surveillance inspections” of facilities and “for-cause inspections to follow up on consumer complaints” noted in letters.

Bioassay Instructions For Tests Using Rats Provided To Bolster US Infant Formula Supply

Draft details modifications to AOAC International’s PER rat bioassay method to show a formula meets quality factor of sufficient biological quality of protein, one factors FDA considers in evaluating submissions.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel